Mahen Gundecha

Mahen Gundecha is a seasoned health sciences leader with extensive business development, alliance management, new product commercialization and franchise P&L leadership experience across a range of companies, including Juno Therapeutics (Celgene), Novartis Group, Novo Nordisk, Endo Pharmaceuticals and GSK. Mahen has had hands on experience building business development strategies in multiple therapeutic areas and has executed foundational deals. Mahen’s most recent experience has involved managing complex global oncology and gene editing partnerships, spanning R&D, manufacturing and commercialization. Mahen brings a broad base of therapeutic experience to Melior, including Neurosciences, Endocrinology, Hematology, Oncology, Rare Diseases, Cell Therapeutics and Gene Editing. Mahen will be leading investment and business development activities at Melior.